Chime Vision Issue 6

Frédéric Bouvier is a senior biopharmaceutical executive with 25+ years of experience in biologics and biosimilars across Sanofi, Fresenius Kabi, biotech startups, and CDMO organizations. His expertise spans corporate strategy, business development, portfolio build-up, and commercialization, with a strong track record of bringing biosimilars to international markets.

In this interview, Peter Pang discusses evolving risks and key considerations for biosimilar CMC amid the growing adoption of CES waivers by regulators.

A prefilled syringe (PFS) is a ready-to-use disposable syringe with a premeasured dose, eliminating the need to draw medication from a vial.

March 2026, Shanghai, China — Chime Biologics, a leading global CDMO that enables its partners' success in biologics, congratulates its partner Hope Medicine Inc. on the successful dosing of the first patient in the Phase III clinical trial of HMI-115, a novel monoclonal antibody developed for the treatment of endometriosis. This milestone was achieved at the lead site, Peking Union Medical College Hospital, in China. The trial is a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the safety and efficacy of HMI-115 in treating moderate to severe pain associated with endometriosis.

Recently, the 2026 Hubei–Korea Future Cooperation Exchange Event was successfully held in Wuhan, China. As an important platform for efficient collaboration between Chinese and Korean industries and capital, the event brought together government agencies, financial institutions, well-known enterprises, and industry representatives from both countries to conduct in-depth exchanges on strategic emerging industries, with a focus on biomedicine.

At this year’s BIO Equity Europe discussions held in Prague, Czech Republic earlier this month, one message resonated consistently across presentations, panels, and investor conversations: the global biotechnology industry is entering a new era defined by artificial intelligence, accelerated innovation efficiency, and strategic global collaboration.

Representing Chime Biologics, Board Director and CEO Jimmy Wei shared the company’s vision in a featured presentation titled “Turning AI into Biologics Reality”, highlighting how Chime Biologics is integrating China’s rapidly advancing AI ecosystem into end-to-end biologics development and manufacturing capabilities.

Wuhan, China & Seoul, South Korea | June 2, 2026 — Chime Biologics, a global biologics CDMO dedicated to enabling partners’ success, and Daewoong Pharmaceutical, a leading South Korean pharmaceutical company, today announced the signing of a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Dupixent.